We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

66 hedge funds and large institutions have $93.2M invested in Protagonist Therapeutics in 2018 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 15 increasing their positions, 31 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 9

8% more funds holding

Funds holding: 61 → 66 (+5)

9.07% less ownership

Funds ownership: 66.36% → 57.29% (-9.1%)

43% less capital invested

Capital invested by funds: $165M → $93.2M (-$71.6M)

52% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 31

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
66
Holders Change
+5
Holders Change %
+8.2%
% of All Funds
1.47%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
17
Increased
15
Reduced
31
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VMI
VHCP Management III
New York
+$3.36M
2
VMI
VHCP Management II
New York
+$1.98M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.35M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.03M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$970K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$7.76M
2
Jennison Associates
Jennison Associates
New York
-$3.6M
3
Millennium Management
Millennium Management
New York
-$2.73M
4
Deutsche Bank
Deutsche Bank
Germany
-$1.6M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.57M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$24.4M +$1.35M +170,500 +5%
FCM
2
Farallon Capital Management
California
$14.8M -$345K -43,528 -2%
BI
3
BVF Inc
California
$11M -$7.76M -978,509 -37%
GPP
4
Great Point Partners
Connecticut
$6.43M -$213K -26,831 -3%
Millennium Management
5
Millennium Management
New York
$4.64M -$2.73M -343,647 -33%
Vanguard Group
6
Vanguard Group
Pennsylvania
$4.44M +$1.03M +129,285 +24%
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$3.3M +$970K +122,250 +33%
VMI
8
VHCP Management III
New York
$2.85M +$3.36M +423,176 New
Renaissance Technologies
9
Renaissance Technologies
New York
$2.29M -$1.57M -197,400 -37%
BlackRock
10
BlackRock
New York
$1.75M +$168K +21,126 +9%
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$1.73M +$51.7K +6,516 +3%
VMI
12
VHCP Management II
New York
$1.68M +$1.98M +250,024 New
TCM
13
Tekla Capital Management
Massachusetts
$1.33M -$174K -21,904 -10%
WCM
14
Wedge Capital Management
North Carolina
$1.26M – – –
JP Morgan Chase
15
JP Morgan Chase
New York
$1.1M -$612K -77,114 -32%
OAM
16
Oxford Asset Management
United Kingdom
$947K -$372K -46,939 -25%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$792K -$1.01K -128 -0.1%
American Century Companies
18
American Century Companies
Missouri
$762K -$277K -34,921 -24%
Two Sigma Advisers
19
Two Sigma Advisers
New York
$647K -$372K -46,900 -33%
SIM
20
Spark Investment Management
New York
$636K -$351K -44,200 -32%
FI
21
Fosun International
China
$609K +$766K +96,513 New
BCM
22
Bridgeway Capital Management
Texas
$576K – – –
Barclays
23
Barclays
United Kingdom
$462K +$544K +68,602 New
Bank of New York Mellon
24
Bank of New York Mellon
New York
$426K – – –
Two Sigma Investments
25
Two Sigma Investments
New York
$385K -$693K -87,341 -60%
1
2 3

PTGX Hedge Fund Activity: Q4 2018 in Review

66 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2018, worth a combined $93.2M — down 43% from $165M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new PTGX positions and 9 closed out — a net gain of 8 holders — while 15 added to existing stakes and 31 trimmed.

The largest buyer was VHCP Management III, opening a new position worth an estimated $3.36M. The largest seller was BVF Inc, cutting an estimated $7.76M.

  • 66 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2018, up from 61 in Q3 2018.
  • Funds reported $93.2M of Protagonist Therapeutics stock for Q4 2018, down 43% quarter-over-quarter.
  • 17 funds opened new Protagonist Therapeutics positions in Q4 2018 and 9 closed out, a net change of +8 holders.
  • The largest Protagonist Therapeutics buyer in Q4 2018 was VHCP Management III, an estimated $3.36M added.
  • The largest Protagonist Therapeutics seller in Q4 2018 was BVF Inc, an estimated $7.76M sold.

Based on aggregated 13F filings for Q4 2018.